An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)
Phase of Trial: Phase I/II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs RO 7112689 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Chugai Pharmaceutical; Roche
- 17 Mar 2018 This trial has been suspended in Italy.
- 05 Mar 2018 Planned primary completion date changed from 17 Feb 2018 to 15 Aug 2018.
- 16 Jan 2018 This trial has been suspended in Germany.